Skip to main content
Article thumbnail
Location of Repository

Retinoid X receptor and peroxisome proliferator-activated receptor-gamma agonists cooperate to inhibit matrix metalloproteinase gene expression

By Peter S Burrage, Adam C Schmucker, Yanqing Ren, Michael B Sporn and Constance E Brinckerhoff
Topics: Research Article
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    1. (1999). A: Preclinical and clinical studies of MMP inhibitors in cancer.
    2. (2005). Aigner T: Comparison of the chondrosarcoma cell line SW1353 with primary human adult articular chondrocytes with regard to their gene expression profile and reactivity to IL-1beta. Osteoarthritis Cartilage
    3. (2001). Allis CD: Translating the histone code. Science
    4. (2001). Bordji K: 15-Deoxy[Delta]12,14-PGJ2, but not troglitazone, modulates IL-1[beta] effects in human chondrocytes by inhibiting NF-[kappa]B and AP-1 activation pathways. FEBS Lett
    5. (2004). Brinckerhoff CE: Overexpression of collagenase 1 (MMP1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling.
    6. (2003). Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats. Arthritis Rheum
    7. (1996). Canalis E: Transcriptional and posttranscriptional regulation of intersti-Arthritis
    8. (2001). CE: A synthetic triterpenoid selectively inhibits the induction of matrix metalloproteinases 1 and 13 by inflammatory cytokines. Arthritis Rheum
    9. (1997). CE: Cell-type specific regulation of human interstitial collagenase-1 gene expression by interleukin-1 beta (IL-1 beta) in human fibroblasts and BC-8701 breast cancer cells.
    10. (2001). CE: IL-1 induces collagenase-3 (MMP-13) promoter activity in stably transfected chondrocytic cells: requirement for Runx-2 and activation by p38 MAPK and JNK pathways. Nucl Acids Res
    11. (2006). CE: Matrix metalloproteinases: role in arthritis. Front Biosci
    12. (1998). CE: Nuclear factor kappaB/ p50 activates an element in the distal matrix metalloproteinase 1 promoter in interleukin-1beta-stimulated synovial fibroblasts. Arthritis Rheum
    13. (2007). CE: Regulation of matrix metalloproteinase gene expression by a retinoid X receptor-specific ligand. Arthritis Rheum
    14. (2005). CE: Short hairpin RNAmediated inhibition of matrix metalloproteinase-1 in MDA-231 cells: effects on matrix destruction and tumor growth. Cancer Res
    15. (2001). Chalbos D: Characterization of the physical interaction between estrogen receptor alpha and JUN proteins.
    16. (2006). Chung CH: Negative modulation of RXR{alpha} transcriptional activity by small ubiquitin-related modifier (SUMO) modification and its reversal by SUMO-specific protease SUSP1.
    17. (2005). CK: A SUMOylationdependent pathway mediates transrepression of inflammatory response genes by PPAR-[gamma]. Nature
    18. (1992). Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors.
    19. (2004). Corvol MT: Peroxisome proliferator-activated receptor-gamma down-regulates chondrocyte matrix metalloproteinase-1 via a novel composite element.
    20. (2004). Desvergne B: In vivo activation of PPAR target genes by RXR homodimers.
    21. (2007). Fahmi H: Peroxisome proliferator-activated receptor gamma1 expression is diminished in human osteoarthritic cartilage and is downregulated by interleukin-1beta in articular chondrocytes. Arthritis Res Ther
    22. (2001). for the Worldwide Bexarotene Study G: Phase 2 and 3 clinical trial of oral bexarotene (targretin capsules) for the treatment of refractory or persistent early-stage cutaneous Tcell lymphoma. Arch Dermatol
    23. (2002). Fradin A: Effects of agonists of peroxisome proliferator-activated receptor [gamma] on proteoglycan degradation and matrix metalloproteinase production in rat cartilage in vitro. Osteoarthritis Cartilage
    24. (2001). Gronemeyer H: The Nuclear Receptor FactsBook London:
    25. (2007). Grunstein M: Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem
    26. (2000). H: 15-deoxydelta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats.
    27. (1996). Heyman RA: Activation of specific RXR heterodimers by an antagonist of RXR homodimers.
    28. (1997). Heyman RA: Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature
    29. (1996). Interaction of the Ubc9 human homologue with c-Jun and with the glucocorticoid receptor. Steroids
    30. (2005). JP: Pioglitazone, a peroxisome proliferatoractivated receptor gamma agonist, reduces the progression of experimental osteoarthritis in guinea pigs. Arthritis Rheum
    31. (2004). K: A potential role of 15-Deoxy-{Delta}12,14-prostaglandin J2 for induction of human articular chondrocyte apoptosis in arthritis.
    32. (2002). Matrisian LM: Matrix metalloproteinase inhibitors and cancer – trials and tribulations. Science
    33. (2004). Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail Rev
    34. (2003). Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev
    35. (2008). MB: Prevention and treatment of experimental estrogen receptornegative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl ester and the rexinoid LG100268. Clin Cancer Res
    36. (2008). MB: The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis. Mol Cancer Ther
    37. (2007). O'Malley BW: Nuclear receptor coregulators and human disease. Endocr Rev
    38. (2001). Peroxisome proliferator – activated receptor gamma activators inhibit interleukin-1beta-induced nitric oxide and matrix metalloproteinase 13 production in human chondrocytes. Arthritis Rheum
    39. (2002). Peroxisome proliferator-activated receptor gamma activators inhibit MMP-1 production in human synovial fibroblasts likely by reducing the binding of the activator protein 1. Osteoarthritis Cartilage
    40. (2006). Protocol for the fast chromatin immunoprecipitation (ChIP) method. Nat Protoc
    41. (2007). RD: Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects.
    42. (2006). Reifel-Miller A: Biological characterization of a heterodimer-selective retinoid X receptor modulator: potential benefits for the treatment of type 2 diabetes. Endocrinology
    43. (2001). Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-[Delta][Delta]CT method. Methods
    44. (1999). Staels B: Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappa B and AP-1.
    45. (2004). Stephens JM: Control of peroxisome proliferator-activated receptor gamma2 stability and activity by SUMOylation. Obes Res
    46. (2000). Terlain B: Evidence for the presence of peroxisome proliferator-activated receptor (PPAR) alpha and gamma and retinoid Z receptor in cartilage. PPARgamma activation modulates the effects of interleukin1beta on rat chondrocytes.
    47. (1996). The peroxisome proliferatoractivated receptors: ligands and activators.
    48. (1995). The RXR heterodimers and orphan receptors. Cell
    49. (1998). TR: Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor. J Bone Joint Surg Br
    50. (2004). Tsukamoto H: Peroxisome proliferator-activated receptor {gamma} induces a phenotypic switch from activated to quiescent hepatic stellate cells.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.